Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Polysaccharide purification from Haemophilus influenzae type b through tangential microfiltration

Full text
Author(s):
Ferreira Albani, Silvia Maria [1] ; da Silva, Mateus Ribeiro [2] ; Fratelli, Fernando [3] ; Cardoso Junior, Celso Preto [4] ; Iourtov, Dmitri [5] ; Cintra, Felipe de Oliveira [6] ; Takagi, Mickie [7] ; Cabrera-Crespo, Joaquin [8]
Total Authors: 8
Affiliation:
[1] Inst Butantan. Lab Bioproc
[2] Inst Butantan. Lab Bioproc
[3] Inst Butantan. Lab Especial Piloto Prod Biol Recombinantes
[4] Inst Butantan. Lab Especial Piloto Prod Biol Recombinantes
[5] Inst Butantan. Div Desenvolvimento Tecnol & Prod
[6] Inst Butantan. Lab Bioproc
[7] Inst Butantan. Lab Bioproc
[8] Inst Butantan. Lab Bioproc
Total Affiliations: 8
Document type: Journal article
Source: Carbohydrate Polymers; v. 116, p. 67-73, FEB 13 2015.
Web of Science Citations: 5
Abstract

Haemophilus influenzae type b (Hib) is a human pathogen that causes meningitis in infants worldwide. Capsular polysaccharide linked to a protein has been used as an efficient vaccine, and this approach has reduced the incidence of Hib disease since its inclusion in national immunisation campaigns. The traditional polysaccharide downstream process is based on several ethanol precipitations, treatment with detergents and centrifugation. The aim of this study was to introduce tangential microfiltration (TMF) in the place of centrifugation to simplify handling and to scale up the process. The purity of the polysaccharide was RPNA = 1747.2 and RPPrt = 196.1 for nucleic acid and protein, respectively, meeting the quality requirements for this polysaccharide. Moreover, the polysaccharide was recognised by at specific antibody, and the ribose and phosphate contents were within the expected limits. Thus, we established a process for the purification of capsular polysaccharide produced by H. influenzae type b that is effective, robust and feasible to be scaling up. (C) 2014 Elsevier Ltd. All rights reserved. (AU)